Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Meliora Therapeutics General Information
Meliora Therapeutics has developed a proprietary computational platform that uses machine learning to identify the true mechanisms-of-action for small molecule oncology drugs. The company aims to improve success rates in oncology drug development by building an atlas of drug mechanisms and developing new therapies based on these insights. As of early 2025, the company has raised $11M in seed funding and advanced multiple preclinical programs but has not yet reported clinical trial results.
Contact Information
Primary Industry
Biotech
Corporate Office
Menlo Park, California
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Meliora Therapeutics Funding
No funding data available
To view Meliora Therapeutics's complete valuation and funding history, request access »